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Abstract
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease of 
unknown cause that affects mainly the motor neurons of the spi-
nal cord, brain stem and brain. The pathogenesis is still obscure and 
the diagnosis is based on patient history and clinical examination. A 
handful of factors have been proposed to be associated with ALS; 
however, the only established risk factors to date are older age, male 
sex, and a family history of ALS. The familial cases have their histo-
rical importance in causative gene identification since through these 
discoveries much has been uncovered about ALS pathogenesis. The 
understanding of clinical and epidemiological factors associated with 
functional impairment is of fundamental for early adoption of mea-
sures to promote a better survival and a better quality of life. Rapid 
diagnosis of amyotrophic lateral sclerosis (ALS) and other neurological 
disorders is vital if future treatments are to be applied at an early di-
sease stage. The current pace of discovery and identification of novel 
disease mechanisms in ALS is unprecedented. Advances in this area, 
however, have also introduced challenges in the heterogeneity of diag-
nostic definitions affecting this patient population.
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Motor neuron disease (MND) is a collective term for a devastating 
group of disorders that result in muscle paralysis through the dege-
neration of motor neurons. Amyotrophic lateral sclerosis (ALS) is the 
most common form of MND, in which affected individuals generally 
die from respiratory failure within 2-5 years of diagnosis. [1, 2] Also 
known as Charcot's disease (France) or Lou Gehrig's disease (USA) is 
a acquired disease and neurodegenerative of unknown cause that 
affects mainly the motor neurons of the spinal cord, brain stem and 
brain. [3]
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ALS is a devastating neurodegenerative disease, 
and luckily, very rare: only one to two people out 
of 100,000 develop ALS yearly. This fact, however, 
makes studies of ALS very challenging since it is very 
difficult to collect the representative set of clinical 
samples and this may take up to several years. The 
pathogenesis is still obscure and the diagnosis is 
based on patient history and clinical examination. 
The mechanism of disease onset in humans is not 
yet fully understood and no effective treatment is 
available at present. Several pathogenic mechanisms 
have been proposed to be involved in the loss of 
the motor neurons in ALS, including oxidative stress, 
excitotoxicity, protein aggregation, and mitochon-
drial dysfunction (Figure 1) [4, 5, 6]. Many efforts 
have been made to find biomarkers to enable earlier 
diagnosis, to monitor disease progression and to 
predict prognosis. [6] (Figure 1)
This disease has a global occurrence, with 120,000 
new cases per year. The survival rate is on average 
of 3-5 years, the prognosis is worse in cases where 
the onset is characterized by bulbar involvement, 
followed by the cases where signs of involvement 
of the upper motor neuron (UMN) or lower motor 
neuron (LMN) first appear in the upper limbs (UL). 
Survival may be slightly higher in younger indivi-
duals and those in which the signs of ALS begin 
in the lower limbs (LL). [3, 7, 8, 9, 10, 11, 12, 13, 
14] The understanding of clinical and epidemiolo-
gical factors associated with functional impairment 
is of fundamental importance for early adoption of 
measures to promote a better survival and a better 
quality of life. [14]
It is believed that the incidence of Amyotrophic 
Lateral Sclerosis (ALS) is the same all over the world, 
however, there is not a well conducted and com-
Figure 1:  Vulnerability factors and mechanism of injury in Motor Neuron Disease. This picture was 
extracted from Brockington A, Shaw P. (2003). [55, 56, 57]. This legend was modified.
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parative study among different populations with 
ALS, among ethnic or geographical area defined 
outside of Europe and North America (Figure 2). 
However, research shows that there are individual 
variations. SLA usually affects more men than wo-
men, although more recent studies show that both 
sexes are affected similarly. Reports of the increase 
in the ALS cases number in women may be related 
to the better population identification with previous 
studies, to the recent effects of a not identified envi-
ronmental exposure, and/or to the lifestyle changes 
causing on them a higher exposition to the potential 
toxics, associated historically with men (smoking, 
occupational exposures). Other risk factors draw 
attention and specially to whom may be related to 
the ALS development, such as exposure to severe 
electrical shock, strenuous physical activity, soldiers 
who served in the first Gulf War and professional 
soccer players. [8] (Figure 2)
The classic disease form is insidious, characterized 
by asymmetric muscle weakness, limbs and tongue 
atrophy, in addition to fasciculations and hyperre-
flexia. Progressively, the reduced muscle strength 
becomes systemic culminating in quadriplegia. [7, 
14, 15, 16, 17] The bulbar symptoms usually arise 
in a disease later stage, being characterized by dys-
phonia, dysarthria, dysphagia, weakness, atrophy 
and language fasciculation and later by respiratory 
failure, the most serious disease symptom and the 
major cause of death. [7, 14, 15, 18]
The Clinical ALS types are: 1. sporadic; 2. Familiar; 
3. ALS plus syndrome; 4. ALS mimicking syndrome; 
5. Syndrome with uncertain significance laboratory 
abnormalities. The diagnostic criteria used for ALS 
were currently established by the El Escorial World 
Federation of Neurology, revised in 1998. There is 
also a sub-classification of the diagnostic criteria El 
Escorial which subdivides ALS in: defined ALS (typi-
cal), probable ALS, possible ALS, suspected ALS. [3]
There are well-established criteria for patients 
in whom the manifestations are restricted to dys-
function solely of the upper motor neuron (primary 
lateral sclerosis), lower motor neuron [progressive 
muscular atrophy (PMA), or bulbar segment (pro-
gressive bulbar palsy). [19-23, 24] There are, howe-
ver, no established criteria for a significant number 
of patients who present and progress with predomi-
nantly upper and only subtle lower motor patholo-
gy, or, conversely, predominantly lower motor with 
only subtle upper motor neuron signs. These patient 
groups can be further prognostically dichotomized 
based on the presence or absence of either bulbar 
or respiratory dysfunction at the time of symptom 
onset, thus expanding the heterogeneous nature of 
the disease. [19, 24, 25, 26] This variability in clini-
cal manifestation at the time of initial assessment 
may be associated with significant variability in sur-
vivorship. Superimposed on this clinical variability is 
the presence or absence of a syndrome of fronto-
temporal dysfunction that may coexist with many 
of the motor neuron disorders and, for several, be 
of prognostic importance. [24, 25] Formal diagnos-
tic criteria for ALS/MND have been developed and 
modified several times. [24, 27-34] In the absence 
of widespread acceptance of diagnostic criteria for 
Figure 2:  Countries and regions with studies 
about Amyotrophic Lateral Sclerosis. 
This picture was adapted from Pereira, 
RDB (2006). [8].
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specific disease subtypes, there have been a num-
ber of clinical phenotypes described. [23, 24, 35-40]
The multisystem involvement of patients affec-
ted by ALS/MND, as well as the varied mechanisms 
attributed to the disease has led to a multitude of 
clinical and biological markers proposed as indices 
of disease progression and/or severity (Figures 1, 3). 
[24, 40-43] Despite this, one of the primary cha-
llenges in studying ALS/MND is the absence of an 
accepted marker with both the appropriate sensi-
tivity and specificity applicable to the wide range 
of affected patients. The result of this void in our 
understanding is a lack of confidence that we can 
reliably measure disease progression or therapeutic 
efficacy in our clinical trials. [24]
Also, the potential for genetic markers as corre-
lates of disease subtype and progression has ge-
nerated much enthusiasm and promise, although 
remains incompletely understood. There are cu-
rrently very few established relationships between 
a specific genetic mutation and a specific pheno-
type. The hope is that a potential etiology, at least 
for a specific phenotype, will emerge and highlight 
a primary disease mechanism. [24, 44, 45, 46, 47]
Rapid diagnosis of amyotrophic lateral sclerosis 
(ALS) and other neurologic disorders is vital if future 
treatments are to be applied at an early disease sta-
ge. For genetic causes of these diseases, the current 
technology lies with sequential Sanger sequencing. 
However, with an array of multiple genes causing 
each disease and, additionally, numerous alterations 
within each gene being potentially harmful, it can 
be time consuming and costly to diagnose a pa-
tient suspected of harboring a detrimental gene-
tic variation (Figure 3). Furthermore, the range of 
genetic tests at each institution can be limited. It 
is now plausible that next-generation sequencing 
(NGS) technologies will eliminate many of these 
issues. To test this possibility, we have developed 
a single comprehensive assay containing 25 genes 
which have, to varying degrees, been implicated in 
ALS. NGS technology shows promise for the diag-
Figure 3:  Genes currently known as associated with ALS classified by common molecular pathways in-
volved in the disease pathophysiology. This picture was extracted from Coatti GC et al. (2015). 
50,58,59 This legend was modified. 
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nosis of both familial and sporadic ALS; our rapid 
high-throughput method is suitable for large scale 
genetic studies. [48]
A handful of factors have been proposed to be 
associated with ALS; however, the only established 
risk factors to date are older age, male sex, and 
a family history of ALS. [49] Identification of risk 
factors, especially non-genetic factors, for ALS has 
proven difficult, and likely reflects the complexity 
of the disease. Over the last two decades, a great 
deal of new knowledge has been gathered on 
ALS, especially in terms of its underlying genetics 
and potential mechanisms implied by these genetic 
findings. In contrast, there is substantial impact of 
non-genetic factors on the etiology of ALS, so far 
little progress has been made in identifying these 
factors with some degree of certainty. An impro-
ved knowledge of non-genetic risk factors for ALS, 
hand-in-hand with our increasing knowledge of 
ALS genetics, should prove more fruitful in deci-
phering the causes of this devastating disease and 
eventually providing a cure. [49] (Figure 3)
ALS is mainly classified into two groups: FALS 
(Familial ALS), for the inherited forms of the disea-
se, and SALS for the sporadic cases, in which there 
are no affected relatives and where in the majority 
of cases it is not possible to identify a single cau-
sative agent. The familial cases have their historical 
importance in causative gene identification since 
through these discoveries much has been unco-
vered about ALS pathogenesis. Around 33 genes 
or chromosomal regions have been linked to ALS, 
providing important clues on the pathophysiological 
mechanisms of the disease (Figures 1, 3). Although, 
environmental conditions could play an important 
role for disease development. [50]
In this context, TBK1 have been implicated as an 
ALS gene, providing insight into disease biology and 
suggesting possible directions for drug screening 
programs. Also, evidence has been provided that 
OPTN plays a broader role in ALS than previously 
recognized. Both TBK1 and OPTN are involved in au-
tophagy, with TBK1 possibly playing a crucial role in 
autophagosome maturation as well as the clearance 
of pathological aggregates. [51, 52, 53] These ob-
servations highlight a critical role of autophagy and/
or inflammation in disease predisposition. It is also 
noteworthy that many drugs have been developed 
that act on TBK1-mediated pathways owing to their 
role in tumor cell survival [53, 54] and can therefore 
be used to investigate the effects of drug-depen-
dent loss of function of the kinase. Although, a large 
genetic dataset for ALS has been provided, which 
suggests other possible ALS genes and provides a 
substantial collection of pathogenic variants across 
ALS genes. After removing the expected number 
of variants to be seen based on the frequencies of 
rare variants in controls, we identify more than 70 
distinct pathogenic mutations across SOD1, OPTN, 
TARDBP, VCP, SPG11, and TBK1 that can be used in 
future efforts to functionally characterize the role of 
these ALS genes. The identification of TBK1 and the 
expanded role for OPTN as ALS genes reinforce the 
growing recognition of the central role of autopha-
gy and neuroinflammation in the pathophysiology 
of ALS. [53]
About 90% of cases are sporadic while about 
10% are hereditary and are Caused by mutations 
in the Super Oxide Dismutase 1 (SOD1), TARDBP 
and FUS genes. [2, 8] The gene therapy attempts to 
ALS have had as major target the defective activity 
of superoxide dismutase correction. These experi-
ments were made possible after the animal models 
development. These experiments still require in vivo 
evidence. This type of therapy for neuromuscular 
diseases promises great advances in the coming 
years, however many obstacles remain to be over-
come; as the large number of vectors required for 
effective treatment; the vectors direction exclusively 
for motor neurons, the continuous expression and 
not just the transgene transient; the defects correc-
tion without toxic side effects and these therapies 
application for various forms of MND and ALS, not 
limited to only a few models. [8]
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Previous research has provided extensive evidence 
of a pivotal role for excitotoxicity in ALS pathophy-
siology. Investigations indicate that raised central 
levels of excitotoxic stimuli could be a primary me-
chanism involved in the degeneration of motor neu-
rons, and therefore indicate that excitotoxicity could 
account for the selective motor neuron death obser-
ved in ALS. Understanding excitotoxic mechanisms 
of neuronal cell loss and NMJ degeneration is a vital 
step in the pathway to developing potential new 
therapeutic interventions for ALS. The data suggest 
that targeted interventions, directed specifically at 
the cell body, might be more efficacious in tackling 
this devastating disease. [1]
Current clinical practice for patients affected by 
ALS/MND includes a combination of proactive, ad-
junctive and symptomatic therapies. Outcome data 
are lacking relative to the number and variety of 
treatments used regularly in this population. While 
treatment approaches are likely more consistent to-
day than they were a decade ago, implementation 
of these often efficacious treatments has introduced 
another source of variability in comparing groups of 
patients for clinical trials. Specifically, maintenance 
of respiratory health, nutritional stability, physical 
safety, and aids to improve daily function have an 
impact on quality of life and disease duration. Whi-
le these benefits have been difficult to measure in 
controlled studies, multidisciplinary care has beco-
me the standard of treatment for this complex mul-
tisystem disease. [4]
The current pace of discovery and identification 
of novel disease mechanisms in ALS/MND is un-
precedented. Despite the great expansion in our 
knowledge base, there remain some fundamen-
tal challenges on issues such as disease definition, 
appropriate biomarkers of disease progression, in-
terpretation of the multitude of genetic mutations 
associated with disease, and the impact of aggres-
sive symptomatic treatment. Identification of fron-
totemporal dysfunction in a majority of patients 
with both familial and sporadic ALS/MND has both 
added greatly to the potential for a common un-
derlying mechanism between ALS and frontotem-
poral dysfunction, while at the same time providing 
an important prognostic determinant. Advances in 
this area, however, have also introduced challenges 
in the heterogeneity of diagnostic definitions affec-
ting this patient population. Our ability to design 
effective clinical trials that will ultimately lead to effi-
cacious therapies will likely depend upon resolution 
of some of these most basic questions of diagnosis 
and disease progression. [4]
References
 1. Blizzard CA et al. Identifying the primary site of pathogenesis 
in amyotrophic lateral sclerosis–vulnerability of lower 
motor neurons to proximal excitotoxicity. Disease Models & 
Mechanisms (2015) 8, 215-224.
 2. Bucchia M et al. Therapeutic Development in Amyotrophic Lateral 
Sclerosis. ClinTher. 2015 Feb 6.pii: S0149-2918(15)00010-7.
 3. Palermo, S et al. Epidemiology of amyotrophic lateral sclerosis - 
Europe/North America/South America/Asia: discrepancies and 
similarities: systematic review of the literature. Rev. bras. neurol; 
45(2): 5-10, abr.-jun. 2009.
 4. Menzies FM, Ince PG, Shaw PJ. Mitochondrial involvement in 
amyotrophic lateral sclerosis. NeurochemInt 2002; 40: 543-51.
 5. Shaw PJ. Molecular and cellular pathways of neurodegeneration 
in motor neurone disease. J NeurolNeurosurg Psychiatry 2005; 
76: 1046-57
 6. Elf K et al. Alterations in muscle proteome of patients diagnosed 
with amyotrophic lateral sclerosis. J Proteomics. 2014 Aug 28; 
108: 55-64.
 7. Mitchell, J. Douglas; BORASIO, GianDomenico. Amyotrophic 
lateral sclerosis. Lancet, London, v. 369, n. 9578, p. 2031-2041, 
2007.
 8. Pereira, RDB. Epidemiologia: ELA no Mundo (Epidemiology: 
ALS in World). V Simpósio Brasileiro de Doença do Neurônio 
Motor/Esclerose Lateral Amiotrófica e I Simpósio Verde vida 
Saúde, 2006, São Paulo. Esclerose Lateral Amiotrófica: sua 
manifestação no Brasil. São Paulo. Revista Neurociências, São 
Paulo, v. 14, n. 2, p. 9-13, 2006. 
 9. Wijesekera, Lokesh C; LEIGH. P. Nigel. Amyotrophic Lateral 
Sclerosis. Orphanet J. Rare Dis., London, v. 4, n. 3, p. 1-22, 2009.
 10. Soriani, M. H.; Desnuelle, Claude. Épidémiologie de la SLA. Rev. 
Neurol., Paris, v. 165, n.8/9, p. 627-640, 2009. 
 11. Logroscino, G. et al. Descriptive epidemiology of amyotrophic 
lateral sclerosis: new evidence and unsolved issues. J. Neurol. 
Neurosurg. Psychiatry, London, v. 79, n. 1, p. 6-11, 2008.
InternatIonal archIves of MedIcIne
Section: neurology 
Issn: 1755-7682
2015
Vol. 8 No. 263
doi: 10.3823/1862
© Under License of Creative Commons Attribution 3.0 License 7
 12. Matias-Guiu J. et al. Descriptive epidemiology of amyotrophic 
lateral sclerosis. Neurologia, Barcelona, v. 22, n. 6, p. 368-380, 
2007. 
 13. Logroscino, G. et al. Incidence of amyotrophic lateral sclerosis in 
Europe. J. Neurol. Neurosurg. Psychiatry, London, v. 81, n. 4, p. 
385-390, 2010.
 14. Alves Cosmo CS et al. Clinical aspects of functional capacity 
determinants in amyotrophic lateral sclerosis. R. Ci. med. biol., 
Salvador, v.11, n.2, p.134-139, mai./set. 2012.
 15. Rowland, Lewis P.; SHNEIDER, Neil. A. Amyotrophic lateral 
sclerosis. N. Engl. J. Med., Boston, v. 344, n. 22, p. 1688-1700, 
2001.
 16. Walling, Anne D. Amyotrophic lateral sclerosis: Lou Gehrig’s 
disease. Am. Fam. Physician, Kansas, v. 59, n. 6, p. 1489-1499, 
1999. 
 17. Anequini, I.P. et al. Avaliação das atividades da ABRELA: 
orientações oferecidas, expectativas atingidas? Rev. 
Neurociências, São Paulo, v. 14, n. 2, p. 57-64, 2006.
 18. Cudkowicz, M. Qureshi M, Shefner J. Measures and markers in 
amyotrophic lateral sclerosis. NeuroRx., Milwaukee, v. 1, n. 1, p. 
273-283, 2004.
 19. Sabatelli, M., M. Zollino, M. Luigetti, et al., Uncovering 
amyotrophic lateral sclerosis phenotypes: clinical features and 
long-term follow-up of upper motor neuron-dominant ALS. 
Amyotrophic Lateral Sclerosis, 2011. 12(4): p. 278-82.
 20. Rosenfeld, J. andM. Swash,What's in a name? Lumping or 
splitting ALS, PLS, PMA and the other motor neuron diseases. 
Neurology, 2006. 66(draft).
 21. Ravits, J.M. and A.R. La Spada, ALS motor phenotype 
heterogeneity, focality, and spread: deconstructing motor 
neuron degeneration. Neurology, 2009. 73(10): p. 805-11. 
 22. Turner, M.R., J. Scaber, J.A. Goodfellow, et al., The diagnostic 
pathway and prognosis in bulbar-onset amyotrophic lateral 
sclerosis. Journal of the Neurological Sciences, 2010. 294(1-2): 
p. 81-5. 
 23. Pringle, C.E., A.J. Hudson, D.G. Munoz, et al., Primary lateral 
sclerosis. Clinical features, neuropathology and diagnostic 
criteria. Brain, 1992. 115(Pt 2): p. 495-520.
 24. Rosenfeld J, Strong MJ. Challenges in the Understanding and 
Treatment of Amyotrophic Lateral Sclerosis/Motor Neuron 
Disease. Neurotherapeutics. 2015. Jan.
 25. Georgoulopoulou, E., N. Fini, M. Vinceti, et al., The impact of 
clinical factors, riluzole and therapeutic interventions on ALS 
survival: a population based study in Modena, Italy. Amyotrophic 
Lateral sclerosis &Frontotemporal Degeneration, 2013. 14(5-6): 
p. 338-45. 33. Katzberg, H
 26. Tartaglia, M.C., A. Rowe, K. Findlater, et al., Differentiation 
between primary lateral sclerosis and amyotrophic lateral 
sclerosis: examination of symptoms and signs at disease onset 
and during follow-up. Archives of Neurology, 2007. 64(2): p. 
232-6.
 27. Strong, M.J., The syndromes of frontotemporal dysfunction 
in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis, 
2008. 9(6): p. 323 - 338.
 28. Brooks, B.R., R. Mikker, M. Swash, and T. Munsat, El Escorial 
revisited: Revised criteria for the diagnosis of amyotrophic lateral 
sclerosis. ALS and Other Motor Neuron Diseases, 2000. 1: p. 
293- 99. 
 29. Traynor, B.J. et al., Clinical features of amyotrophic lateral 
sclerosis according to the El Escorial and Airlie House diagnostic 
criteria: A population-based study. Archives of Neurology, 2000. 
57(8): p. 1171-1176. 
 30. Boekestein, W.A., B.U. Kleine, G. Hageman, H.J. Schelhaas, 
and M.J. Zwarts, Sensitivity and specificity of the 'Awaji' 
electrodiagnostic criteria for amyotrophic lateral sclerosis: 
retrospective comparison of the Awaji and revised El Escorial 
criteria for ALS. Amyotrophic Lateral Sclerosis, 2010. 11(6): p. 
497-501. 
 31. Carvalho, M.D. and M. Swash, Awaji diagnostic algorithm 
increases sensitivity of El Escorial criteria for ALS diagnosis. 
Amyotrophic Lateral Sclerosis, 2009. 10(1): p. 53-7. 
 32. Costa, J., M. Swash, and M. de Carvalho, Awaji criteria for the 
diagnosis of amyotrophic lateral sclerosis: a systematic review. 
Archives of Neurology, 2012. 69(11): p. 1410-6. 
 33. Higashihara, M., M. Sonoo, I. Imafuku, et al., Fasciculation 
potentials in amyotrophic lateral sclerosis and the diagnostic 
yield of the Awaji algorithm. Muscle & Nerve, 2012. 45(2): p. 
175-82. 
 34. Strong, M.J., G.M. Grace, M. Freedman, et al., Consensus criteria 
for the diagnosis of frontotemporal cognitive and behavioural 
syndromes in amyotrophic lateral sclerosis. [Erratum appears in 
Amyotroph Lateral Scler. 2009 Aug; 10(4): 252]. Amyotrophic 
Lateral Sclerosis, 2009. 10(3): p. 131-46.
 35. Beghi, E., A. Chio, P. Couratier, et al., The epidemiology 
andtreatment of ALS: focus on the heterogeneity of the disease 
andcritical appraisal of therapeutic trials. Amyotrophic Lateral 
Sclerosis, 2011. 12(1): p. 1-10
 36. Swash, M. and J. Desai, Motor neuron disease: Classification 
and nomenclature. Amyotrophic Lateral Sclerosis, 2000. 1(2): p. 
105 - 112.
 37. Swash, M. and J. Desai, Motor neuron disease: classification and 
nomenclature. Amyotrophic Lateral Sclerosis & Other Motor 
Neuron Disorders, 2000. 1(2): p. 105-12. 
 38. Chio, A., A. Calvo, C. Moglia, et al., Phenotypic heterogeneity of 
amyotrophic lateral sclerosis: a population based study. Journal 
of Neurology, Neurosurgery & Psychiatry, 2011. 82(7): p. 740-6. 
 39. Hu, M., C. Ellis, A. Al-Chalabi, P. Leigh, and C. Shaw, Flail arm 
syndrome: a distinctive variant of amyotrophic lateral sclerosis. J 
NeurolNeurosurg Psychiatry, 1998. 65: p. 950-951.
 40. Kobayashi, Z., K. Tsuchiya, T. Arai, et al., Pseudopolyneuritic 
form of ALS revisited: clinical and pathological heterogeneity. 
Neuropathology, 2010. 30(4): p. 372-80.
InternatIonal archIves of MedIcIne
Section: neurology 
Issn: 1755-7682
2015
Vol. 8 No. 263
doi: 10.3823/1862
This article is available at: www.intarchmed.com and www.medbrary.com 8
 41. Turner, M.R., R. Bowser, L. Bruijn, et al., Mechanisms, models 
and biomarkers in amyotrophic lateral sclerosis. Amyotrophic 
Lateral sclerosis &Frontotemporal Degeneration, 2013. 14 Suppl 
1: p. 19-32.
 42. Bede, P., A.L.W. Bokde, S. Byrne, et al., Spinal cord markers in 
ALS: diagnostic and biomarker considerations. Amyotrophic 
Lateral Sclerosis, 2012. 13(5): p. 407-15.
 43. Bowser, R., M.R. Turner, and J. Shefner, Biomarkers in 
amyotrophic lateral sclerosis: opportunities and limitations. 
Nature Reviews Neurology, 2011. 7(11): p. 631-8.
 44. Su, X.W., J.R. Broach, J.R. Connor, G.S. Gerhard, and Z. 
Simmons, Genetic heterogeneity of amyotrophic lateral 
sclerosis: implications for clinical practice and research. Muscle 
& Nerve, 2014. 49(6): p. 786-803.
 45. Sabatelli, M., A. Conte, and M. Zollino, Clinical and genetic 
heterogeneity of amyotrophic lateral sclerosis. Clinical Genetics, 
2013. 83(5): p. 408-16
 46. Abel, O., J.F. Powell, P.M. Andersen, and A. Al-Chalabi, ALSoD: 
A user-friendly online bioinformatics tool for amyotrophic lateral 
sclerosis genetics. Human Mutation, 2012. 33(9): p. 1345-51. 
Challenges in Understanding and Treatment of ALS/MND
 47. Renton, A.E., A. Chio, and B.J. Traynor, State of play in 
amyotrophic lateral sclerosis genetics. Nature Neuroscience, 
2014. 17(1): p. 17-23. 
 48. Morgan S et al. Investigation of next-generation sequencing 
technologies as a diagnostic tool for amyotrophic lateral 
sclerosis. Neurobiol Aging. 2015 Mar; 36(3): 1600.e5-8.
 49. Ingre C et al. Risk factors for amyotrophic lateral sclerosis. 
Clinical Epidemiology 2015, Feb; 7: 181-193.
 50. Coatti GC et al. Stem cells for amyotrophic lateral sclerosis 
modeling and therapy: Myth or fact? Cytometry A. 2015 Mar; 
87(3): 197-211.
 51. M. Pilli, J. Arko-Mensah, M. Ponpuak, E. Roberts, S. Master, 
M. A. Mandell, N. Dupont, W. Ornatowski, S. Jiang, S. B. 
Bradfute, J. A. Bruun, T. E. Hansen, T. Johansen, V. Deretic, 
TBK-1 promotes autophagy-mediated antimicrobial defense by 
controlling autophagosome maturation. Immunity 37, 223-234 
(2012).
 52. J. Korac, V. Schaeffer, I. Kovacevic, A. M. Clement, B. Jungblut, 
C. Behl, J. Terzic, I. Dikic, Ubiquitin-independent function of 
optineurin in autophagic clearance of/sciencemag.org/content/
early/recent/19 February 2015/Page 6/10.1126/science.aaa3650 
protein aggregates. J. Cell Sci. 126, 580-592 (2013).
 53. Cirulli ET et al. Exome sequencing in amyotrophic lateral sclerosis 
identifies risk genes and pathways. Science.2015 Feb 19.
 54. J. Li, J. Huang, J. H. Jeong, S. J. Park, R. Wei, J. Peng, Z. Luo, Y. T. 
Chen, Y. Feng, J. L. Luo, Selective TBK1/IKKi dual inhibitors with 
anticancer potency. Int. J. Cancer 134, 1972-1980 (2014).
 55. Brockington A, Shaw P. Developments in the treatment of 
Motor Neurone Disease. ACNR, 2003, nov/dez, 3(5): 13-19.
 56. Shaw PJ, Eggett CJ. Molecular factors underlying selective 
vulnerability of motor neurons to neurodegeneration in 
amyotrophic lateral sclerosis. J Neurol. 2000; 247 Suppl 1: I 17-27
 57. Shaw PJ. Mechanisms of cell death and treatment prospects in 
motor neuron disease. Hong Kong Med J. 2001; 7: 267-280
 58. Robberecht W, Philips T. The changing scene of amyotrophic 
lateral sclerosis. Nat Rev Neurosci 2013; 14: 248-264. 
 59. Ferraiuolo L, Kirby J, Grierson AJ, Sendtner M, Shaw PJ. 
Molecular pathways of motor neuron injury in amyotrophic 
lateral sclerosis. Nat RevNeurol2011; 7: 616-630.
 
 
Where Doctors exchange clinical experiences,
review their cases and share clinical knowledge.
You can also access lots of medical publications for
free. Join Now!
http://medicalia.org/
Comment on this article:
International Archives of Medicine is an open access journal 
publishing articles encompassing all aspects of medical scien-
ce and clinical practice. IAM is considered a megajournal with 
independent sections on all areas of medicine. IAM is a really 
international journal with authors and board members from all 
around the world. The journal is widely indexed and classified 
Q1 in category Medicine.
Publish with iMedPub
http://www.imed.pub
